# BPC-157: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on BPC-157 — the stable gastric pentadecapeptide marketed for tendon, gut and wound healing. Deep preclinical data, no completed human RCT, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
BPC-157 has an unusually deep and internally consistent *animal* evidence base for tissue repair and gut healing, but **no completed human randomized controlled trial exists** — so its highest evidence grade is **C (preclinical only)**. It is not FDA-approved, sits in a 2026 regulatory gray zone, and is prohibited in sport at all times under WADA.[1](https://peptidevox.com/#r1)[14](https://peptidevox.com/#r14)

BPC-157 ("Body Protection Compound-157," PL 14736, Bepecin) is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice, marketed and used as a tissue-repair agent for tendon and ligament injury, gut healing, and wound recovery.[1](https://peptidevox.com/#r1) Its popularity in fitness and recovery circles is enormous; its proof in humans is not. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. BPC-157 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is BPC-157 and how does it work?

BPC-157 is a stable gastric pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.55 Da), a partial fragment of the larger Body Protection Compound found in human gastric juice, first described by Sikirić and colleagues in 1993.[1](https://peptidevox.com/#r1) Its triple-proline motifs and N-terminal glycine confer unusual resistance to proteolysis, which underlies its reported stability in water and gastric juice and is the rationale for oral use in gut indications.[1](https://peptidevox.com/#r1)

The core mechanism — all of it preclinical — centers on the nitric-oxide and angiogenesis axis. In a rat hind-limb ischemia model, BPC-157 increased expression of VEGF receptor-2 (VEGFR2) and accelerated blood-flow recovery, with rapid phosphorylation of eNOS in vascular endothelium.[2](https://peptidevox.com/#r2) The proposed cascade is BPC-157 to VEGFR2 to Akt to eNOS to nitric oxide, producing endothelial proliferation, migration and tube formation.[2](https://peptidevox.com/#r2) A complementary Src-Caveolin-1-eNOS pathway has also been described.[3](https://peptidevox.com/#r3) Other reported signaling includes FAK-paxillin-driven cell migration, growth-hormone-receptor upregulation in tendon fibroblasts, antioxidant-protein induction, and dopaminergic and serotonergic modulation in CNS models.[6](https://peptidevox.com/#r6) In animals the elimination half-life is under about 30 minutes; no validated human pharmacokinetic data exist.[1](https://peptidevox.com/#r1)

## What is the evidence by indication?

A 2025 systematic review of musculoskeletal applications identified 35 preclinical studies and only 1 clinical study, with no completed Phase 2/3 human trials.[19](https://peptidevox.com/#r19) Every indication below is therefore best understood as animal-model evidence, graded C.

  BPC-157 evidence by indication

    IndicationBest evidenceGrade

    Tendon / ligament & tendon-to-bone repairRat Achilles-detachment & transection models (functional, biomechanical, histological gains)C (preclinical)
    Gastrointestinal healing (ulcers, colitis, NSAID toxicity)Multiple animal models; sparse, unpublished early human IBD signalC (preclinical)
    Muscle & wound healingRat muscle-crush & quadriceps-detachment reattachment modelsC (preclinical)
    CNS / neuroprotection & cytoprotectionAnimal antidepressant-like, hepatoprotective & ischemia modelsC (preclinical)
    Knee / joint painOne retrospective 12-patient series, judged unreliable by reviewersD-to-C

The orthopedic evidence is the most cited and the most extrapolated. In a rat Achilles-detachment model, BPC-157 improved healing functionally, biomechanically and histologically, and recovered tendon-to-bone that did not heal spontaneously.[4](https://peptidevox.com/#r4) A separate transection study in 72 rats showed early functional recovery via combined anti-inflammatory action and new blood-vessel formation.[5](https://peptidevox.com/#r5) Muscle models show angiogenesis and restored muscle-to-bone reattachment.[7](https://peptidevox.com/#r7) The gut indication is the peptide's origin: animal models show healing of ulcers, experimental colitis and NSAID-induced lesions, and early-2000s Croatian work explored BPC-157 (as PL 14736) for inflammatory bowel disease — but those human data are sparse and do not constitute completed, reportable RCTs.[10](https://peptidevox.com/#r10)

The only published human data are tiny safety pilots, not efficacy studies. An earlier Phase 1 safety/PK study (NCT02637284) had its results submission cancelled in 2016, leaving no usable public data.[1](https://peptidevox.com/#r1) A 2025 IV pilot (n=2) gave 10 mg then 20 mg infusions with no adverse effects and no biomarker changes — a safety signal only.[8](https://peptidevox.com/#r8) The first controlled efficacy trial, a Phase 2 RCT of subcutaneous BPC-157 for acute grade-II hamstring strain, is registered as [NCT07437547](https://clinicaltrials.gov/study/NCT07437547) but had not reported at the time of writing.[9](https://peptidevox.com/#r9)

Proven vs hyped
Proven in humans: nothing yet. Hyped: most consumer "healing" claims, which extrapolate animal findings. The newly registered Phase 2 hamstring RCT is the development to watch — until it reports, BPC-157 remains an experimental, preclinical-stage compound.[9](https://peptidevox.com/#r9)

## What doses appear in the literature?

Reported strictly as information, not a protocol. No published human dose-finding trial exists, so human dosing is extrapolated from animal work and clinician or community reports.[1](https://peptidevox.com/#r1) Animal studies typically dose in microgram-per-kilogram to nanogram-per-kilogram ranges, once daily, by intraperitoneal, intramuscular, oral or local routes.[4](https://peptidevox.com/#r4) Reported human subcutaneous use is commonly cited around 250 micrograms once or twice daily, with a higher band near 500 micrograms twice daily in acute-injury research planning — research-planning extrapolations, not validated human regimens.[1](https://peptidevox.com/#r1) Oral use is reported for gastrointestinal indications on the basis of reported gastric-juice stability.[1](https://peptidevox.com/#r1) The only published human IV exposure used 10 to 20 mg infused over an hour.[8](https://peptidevox.com/#r8) Animal data note pain and possible necrosis when injected in aqueous or saline solution — a formulation consideration flagged in the safety literature.[1](https://peptidevox.com/#r1)

## How safe is BPC-157?

Human safety data are extremely limited; fewer than about 30 people have been studied across all published reports, so rare or long-term events would not have been detected.[18](https://peptidevox.com/#r18) Preclinically the animal safety profile is favorable: no lethal dose established up to 20 mg/kg in rats, well-tolerated repeated dosing, and no genotoxicity or embryo-fetal toxicity signals.[11](https://peptidevox.com/#r11) The dominant theoretical risk is mechanistic — as a pro-angiogenic agent acting via VEGFR2 and EGR-1, BPC-157 could theoretically promote tumor angiogenesis, a serious caution for anyone with active or prior malignancy.[1](https://peptidevox.com/#r1) Pregnancy, breastfeeding and pediatric use are precautionary contraindications. In practice the largest risk is often product purity: because no FDA-regulated pharmacy may currently compound it, users obtain it from research-chemical vendors whose vials have tested positive for endotoxins, heavy metals and inaccurate dosages.[17](https://peptidevox.com/#r17)

## What is the FDA and WADA status in 2026?

BPC-157 is not an FDA-approved drug and has no USP/NF monograph.[12](https://peptidevox.com/#r12) The regulatory timeline is precise: in September 2023 the FDA moved 19 compounded peptides — including BPC-157 — into 503A Category 2, effectively prohibiting their use as bulk substances.[13](https://peptidevox.com/#r13) On April 15, 2026 the FDA removed 11 peptides, including BPC-157, from Category 2 — but because the nominations were withdrawn, not because the substances were found safe, placing BPC-157 in a gray zone: no longer prohibited, but not authorized.[13](https://peptidevox.com/#r13) A Pharmacy Compounding Advisory Committee review is scheduled for July 23, 2026.[12](https://peptidevox.com/#r12) The critical legal point: removal from Category 2 does not equal Category 1 status and does not authorize compounding.[13](https://peptidevox.com/#r13)

For athletes the picture is unambiguous. BPC-157 has been on the WADA Prohibited List since 2022 under category S0 (non-approved substances) — prohibited at all times, with no Therapeutic Use Exemption.[14](https://peptidevox.com/#r14) It is detectable by mass spectrometry, real sanctions have been imposed, and the NFL, UFC and U.S. Department of Defense all prohibit it.[16](https://peptidevox.com/#r16) Any WADA-tested athlete or service member should treat BPC-157 as banned.[15](https://peptidevox.com/#r15)

**Bottom line.** BPC-157 pairs a deep, coherent animal evidence base with a near-total absence of human proof. From a regenerative standpoint the rationale is appealing, but the gap between promise and proof is the headline — graded C, legally unsettled, and banned in sport. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.

---
Source: https://peptidevox.com/peptide-encyclopedia/bpc-157
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt